FDA Approves PiaSky (crovalimab-akkz) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Follow Drugslib on

FDA Approves PiaSky (crovalimab-akkz) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

June 24, 2024 -- The U.S. Food and Drug Administration (FDA) has approved PiaSky (crovalimab-akkz) for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood condition in which red blood cells are destroyed by the body's complement system (part of the innate immune system). This causes symptoms such as anemia, fatigue and blood clots, and can lead to kidney disease.

Complement C5 inhibitors, which work by blocking part of the complement system cascade, have been shown to be effective in treating PNH. PiaSky contains crovalimab-akkz which is a C5 inhibitor that is recycled within the bloodstream, enabling sustained complement inhibition through low-dose administration every four weeks.

PiaSky is administered as a single loading dose by intravenous infusion on Day 1, followed by four additional weekly loading doses administered by subcutaneous injection on Days 2, 8, 15, and 22. Maintenance dosing starts on Day 29 and is administered every 4 weeks by subcutaneous injection.

The product label for PiaSky carries a Boxed Warning for an increases the risk of serious and life-threatening infections caused by Neisseria meningitidis.

PiaSky is only available through a restricted program called the PiaSky REMS.Warnings and precautions associated with PiaSky include type III hypersensitivity reactions in patients switching from another C5 inhibitor, an increased susceptibility to serious infections, and infusion and injection-related reactions.

Common adverse reactions (incidence ≥10%) were infusion-related reaction, respiratory tract infection, viral infection, and Type III hypersensitivity reactions.

The FDA granted the approval of PiaSky to Genentech, Inc.

Posted : 2024-06-25 05:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords